ENvue Medical is a two-division medical device company formed in February 2025 through the merger of legacy NanoVibronix with an enteral feeding navigation company. The company's primary growth focus is the ENvue Division, which sells the ENvue System — an FDA-cleared electromagnetic navigation platform that guides feeding tube insertion in hospitalized patients. The system emits low-frequency electromagnetic waves to track sensors embedded in a proprietary disposable feeding tube, displaying the tube's path in real time and alerting clinicians if the tube enters the airway, reducing the risk of accidental lung placement. ENvue sells to U.S. acute care hospitals, targeting ICUs. The business model follows a razor-and-blades structure: ENvue places the hardware console at hospitals, sometimes at no charge, in exchange for commitments to purchase proprietary single-use feeding tubes, which are the only tubes cleared for use with the system. Revenue scales with the installed base of hospitals and procedure volumes. The legacy Nano OpCo division sells two ultrasound-based devices — PainShield, a portable patch for pain management, and UroShield, a device that clips onto urinary catheters to reduce biofilm and infection. Both use a similar hardware-plus-consumables model and sell primarily through third-party distributors. Nano OpCo is subscale; PainShield lacks CMS reimbursement, limiting U.S. adoption, while UroShield lacks FDA clearance for U.S. sale but recently gained NHS Drug Tariff reimbursement in the UK. ENvue's pipeline includes pediatric feeding tube versions, imaging-integrated navigation, and a robotic arm platform for automated bedside navigation.